Financiere des Professionnels Fonds d investissement inc. Acquires New Shares in Medpace Holdings, Inc. $MEDP

Key Points

• Financiere des Professionnels Fonds d'investissement inc. acquired 732 shares of Medpace Holdings, Inc. worth approximately $230,000 in the 2nd quarter, indicating increasing institutional interest in the company.
• Several hedge funds boosted their positions in Medpace, with 77.98% of shares owned by institutional investors, reflecting strong confidence in the company's performance.
• Medpace's stock recently reported a 12-month high of $506.55, with analysts adjusting their price targets significantly, indicating positive expectations for the company's future earnings.

Financiere des Professionnels Fonds d investissement inc. bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 732 shares of the company's stock, valued at approximately $230,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MEDP. Whittier Trust Co. grew its holdings in shares of Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after buying an additional 35 shares in the last quarter. Benjamin Edwards Inc. grew its position in Medpace by 3.1% during the first quarter. Benjamin Edwards Inc. now owns 1,201 shares of the company's stock valued at $366,000 after acquiring an additional 36 shares during the period. Geneos Wealth Management Inc. increased its stake in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after acquiring an additional 37 shares during the last quarter. Assetmark Inc. increased its stake in Medpace by 24.9% during the first quarter. Assetmark Inc. now owns 216 shares of the company's stock worth $66,000 after acquiring an additional 43 shares during the last quarter. Finally, Proficio Capital Partners LLC raised its holdings in shares of Medpace by 6.4% in the 1st quarter. Proficio Capital Partners LLC now owns 777 shares of the company's stock worth $237,000 after purchasing an additional 47 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Price Performance

MEDP traded down $0.52 on Monday, reaching $498.08. The company's stock had a trading volume of 155,847 shares, compared to its average volume of 439,644. The stock has a market cap of $13.99 billion, a price-to-earnings ratio of 37.03, a price-to-earnings-growth ratio of 3.14 and a beta of 1.44. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $506.55. The business's 50 day moving average is $446.89 and its 200 day moving average is $355.45.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The company had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. During the same period in the previous year, the business earned $2.75 EPS. Medpace's revenue for the quarter was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Activity at Medpace

In other news, President Jesse J. Geiger sold 41,801 shares of Medpace stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $453.11, for a total value of $18,940,451.11. Following the completion of the transaction, the president owned 36,503 shares in the company, valued at approximately $16,539,874.33. This trade represents a 53.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Kevin M. Brady sold 12,000 shares of the firm's stock in a transaction on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total value of $5,450,760.00. Following the transaction, the chief financial officer owned 6,000 shares in the company, valued at $2,725,380. This trade represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 161,266 shares of company stock worth $74,111,427 over the last quarter. 20.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on MEDP shares. Mizuho increased their target price on shares of Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Jefferies Financial Group raised their target price on shares of Medpace from $400.00 to $450.00 and gave the company a "hold" rating in a research note on Tuesday, September 9th. TD Cowen restated a "sell" rating and set a $366.00 target price (up previously from $283.00) on shares of Medpace in a report on Wednesday, July 23rd. Barclays boosted their price objective on Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 23rd. Finally, Rothschild & Co Redburn lowered Medpace from a "buy" rating to a "neutral" rating and increased their target price for the company from $342.00 to $474.00 in a research note on Wednesday, September 3rd. Two analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Reduce" and a consensus price target of $422.27.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.